Left ventricular assist device and drug therapy for the reversal of heart failure.

By E. Birks, P. Tansley, J. Hardy, Robert S. George, C. Bowles, M. Burke, N. Banner, A. Khaghani, Magdi Yacoub. New England Journal of Medicine, 2006

796 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 (2012, background): “This outcome may occur in some patients with non-ischaemic cardiomyopathy, but is more likely in patients with an acute fulminant, but reversible, cause of HF such as acute myocarditis.(256) Another concept is using MCS to permit recovery of end-organ dysfunction, so-called ‘bridge to candidacy (BTC”
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2016, positive): “This outcome is more likely in younger patients with an acute fulminant but reversible cause of HF, such as acute myocarditis or peripartum cardiomyopathy.(608,609) LVADs may also be used as a ‘bridge to candidacy’ (BTC) in order to permit recovery of end-organ dysfunction, improve RV function and r”